Physician profile
Rita Verma
NPI 1699744649
$2,068.73
in general payments reported to CMS, 2019-2025
23 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $149 · 2021: $668 · 2022: $527 · 2023: $301 · 2024: $155 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $426.78 | 2020-2025 | Hydrus Microstent, Rocklatan, Total30 |
| Regeneron Healthcare Solutions, INC. | $248.38 | 2019-2023 | Eylea |
| Kala Pharmaceuticals, INC. | $234.18 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $202.23 | 2020-2023 | |
| Allergan, INC. | $119.65 | 2019-2022 | |
| Oyster Point Pharma, INC. | $116.82 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $116.55 | 2024 | Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.49 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $96.95 | 2019-2021 | |
| Abbvie INC. | $62.97 | 2023 | Durysta, Ozurdex |
| Sun Pharmaceutical Industries INC. | $54.14 | 2019-2022 | |
| Biotissue Holdings INC. | $52.59 | 2020-2022 | |
| Apellis Pharmaceuticals, INC. | $39.24 | 2023 | Syfovre |
| Eyevance Pharmaceuticals LLC | $28.66 | 2022-2023 | Flarex |
| Johnson & Johnson Vision Care, INC. | $25.90 | 2023 | Acuvue |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $23.17 | 2024 | Clariti Contact Lens |
| Shire North American Group INC | $19.75 | 2019 | |
| Celularity INC. | $19.67 | 2021 | |
| Omeros Corporation | $18.03 | 2019 | |
| Dompe US, INC. | $16.60 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $15.96 | 2025 | Xdemvy |
| Ocular Therapeutix, INC. | $14.53 | 2023 | Dextenza |
| Avedro INC. | $9.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.